5/18/2026

Janusmed amning

Janusmed amning – Kaftrio

Janusmed amning tillhandahåller generella rekommendationer om huruvida ett friskt fullgånget spädbarn kan ammas när modern använder olika läkemedel. Observera att prematura och/eller sjuka spädbarn alltid kräver särskilda överväganden. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed amning och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Elexakaftor

Elexakaftor

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Collins B, Fortner C, Cotey A, Jr CRE, Trimble A. Drug exposure to infants born to mothers taking Elexacaftor, Tezacaftor, and Ivacaftor. J Cyst Fibros. 2021;21(21):S1569-1993(21)02161-5.

  2. Ripani P, Mucci M, Pantano S, Di Sabatino M, Collini F, Ferri G et al. Maternal, newborn and breast milk concentrations of elexacaftor/tezacaftor/ivacaftor in a F508del heterozygous woman with cystic fibrosis following successful pregnancy. Front Med (Lausanne). 2023;10:1274303.

  3. Jain R, Wolf A, Molad M, Taylor-Cousar J, Esther CR, Shteinberg M. Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feeding. J Cyst Fibros. 2022;21(6):1074-1076.

  4. Goodwin J, Quon BS, Wilcox PG. Experience to date with CFTR modulators during pregnancy and breastfeeding in the British Columbia Cystic Fibrosis clinic. Respir Med Case Rep. 2022;40:101778.

  5. Bergeron S, Audousset C, Bourdon G, Garabedian C, Gautier S. Elexacaftor/tezacaftor/ivacaftor induced liver enzymes abnormalities in breastfed infants: A series of 3 cases. Therapie. 2024

  6. Taylor-Cousar JL, Jain R. Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation. J Cyst Fibros. 2021;20(3):402-406.

  7. Kolaczkowski TJ, Bevan A, Legg J, Self J, Allenby M. Elevated liver function tests in infants exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breastfeeding - Case reports. J Cyst Fibros. 2024

  8. Fortner CN, Seguin JM, Kay DM. Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy. J Cyst Fibros. 2021;20(5):835-836.

  9. D'Atri V, Corrado F, Versace F, Saldanha SA, Mercier T, Guidi M et al. A Liquid Chromatography-Tandem Mass Spectrometry Method for the Quantification of Cystic Fibrosis Drugs (Caftors) in Plasma and Its Application for Therapeutic Monitoring. Molecules. 2025;30(9):.

  10. Destoop M, Brantner C, Wilms EB, Tytgat S, Peels B, van der Graaf R et al. CFTR modulator therapy via carrier mother to treat meconium ileus in a F508del homozygous fetus: Insights from an unsuccessful case. J Cyst Fibros. 2025;24(3):476-478.

  11. Sinkey RG, Garcia B, Fowler CM, Krick S, Ryan KJ, Acosta EP et al. Pharmacokinetic assessment of elexacaftor/tezacaftor/ivacaftor and their metabolites in maternal blood, cord blood, the neonate, and breastmilk of a cystic fibrosis carrier mother/affected fetus dyad. J Cyst Fibros. 2026;25(1):28-31.

  12. Gariti A, Johnson R, Moonnumakal S, Placencia F, Sawyer K, Mann DG. Harm reduction in paediatric off-label therapy: ethical analysis of early CFTR modulator use in an infant with cystic fibrosis. J Med Ethics. 2026.

  1. Collins B, Fortner C, Cotey A, Jr CRE, Trimble A. Drug exposure to infants born to mothers taking Elexacaftor, Tezacaftor, and Ivacaftor. J Cyst Fibros. 2021;21(21):S1569-1993(21)02161-5.
  2. Ripani P, Mucci M, Pantano S, Di Sabatino M, Collini F, Ferri G et al. Maternal, newborn and breast milk concentrations of elexacaftor/tezacaftor/ivacaftor in a F508del heterozygous woman with cystic fibrosis following successful pregnancy. Front Med (Lausanne). 2023;10:1274303.
  3. Jain R, Wolf A, Molad M, Taylor-Cousar J, Esther CR, Shteinberg M. Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feeding. J Cyst Fibros. 2022;21(6):1074-1076.
  4. Goodwin J, Quon BS, Wilcox PG. Experience to date with CFTR modulators during pregnancy and breastfeeding in the British Columbia Cystic Fibrosis clinic. Respir Med Case Rep. 2022;40:101778.
  5. Bergeron S, Audousset C, Bourdon G, Garabedian C, Gautier S. Elexacaftor/tezacaftor/ivacaftor induced liver enzymes abnormalities in breastfed infants: A series of 3 cases. Therapie. 2024
  6. Taylor-Cousar JL, Jain R. Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation. J Cyst Fibros. 2021;20(3):402-406.
  7. Kolaczkowski TJ, Bevan A, Legg J, Self J, Allenby M. Elevated liver function tests in infants exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breastfeeding - Case reports. J Cyst Fibros. 2024
  8. Fortner CN, Seguin JM, Kay DM. Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy. J Cyst Fibros. 2021;20(5):835-836.
  9. D'Atri V, Corrado F, Versace F, Saldanha SA, Mercier T, Guidi M et al. A Liquid Chromatography-Tandem Mass Spectrometry Method for the Quantification of Cystic Fibrosis Drugs (Caftors) in Plasma and Its Application for Therapeutic Monitoring. Molecules. 2025;30(9):.
  10. Destoop M, Brantner C, Wilms EB, Tytgat S, Peels B, van der Graaf R et al. CFTR modulator therapy via carrier mother to treat meconium ileus in a F508del homozygous fetus: Insights from an unsuccessful case. J Cyst Fibros. 2025;24(3):476-478.
  11. Sinkey RG, Garcia B, Fowler CM, Krick S, Ryan KJ, Acosta EP et al. Pharmacokinetic assessment of elexacaftor/tezacaftor/ivacaftor and their metabolites in maternal blood, cord blood, the neonate, and breastmilk of a cystic fibrosis carrier mother/affected fetus dyad. J Cyst Fibros. 2026;25(1):28-31.
  12. Gariti A, Johnson R, Moonnumakal S, Placencia F, Sawyer K, Mann DG. Harm reduction in paediatric off-label therapy: ethical analysis of early CFTR modulator use in an infant with cystic fibrosis. J Med Ethics. 2026.

Innehållet senast uppdaterat 4/29/2026

2 2
2 2

Ivakaftor

Ivakaftor

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Trimble A, McKinzie C, Terrell M, Stringer E, Esther CR. Measured fetal and neonatal exposure to Lumacaftor and Ivacaftor during pregnancy and while breastfeeding. J Cyst Fibros. 2018;17(6):779-782.

  2. Collins B, Fortner C, Cotey A, Jr CRE, Trimble A. Drug exposure to infants born to mothers taking Elexacaftor, Tezacaftor, and Ivacaftor. J Cyst Fibros. 2021;21(21):S1569-1993(21)02161-5.

  3. Ripani P, Mucci M, Pantano S, Di Sabatino M, Collini F, Ferri G et al. Maternal, newborn and breast milk concentrations of elexacaftor/tezacaftor/ivacaftor in a F508del heterozygous woman with cystic fibrosis following successful pregnancy. Front Med (Lausanne). 2023;10:1274303.

  4. Jain R, Wolf A, Molad M, Taylor-Cousar J, Esther CR, Shteinberg M. Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feeding. J Cyst Fibros. 2022;21(6):1074-1076.

  5. Goodwin J, Quon BS, Wilcox PG. Experience to date with CFTR modulators during pregnancy and breastfeeding in the British Columbia Cystic Fibrosis clinic. Respir Med Case Rep. 2022;40:101778.

  6. Bergeron S, Audousset C, Bourdon G, Garabedian C, Gautier S. Elexacaftor/tezacaftor/ivacaftor induced liver enzymes abnormalities in breastfed infants: A series of 3 cases. Therapie. 2024

  7. Nash EF, Middleton PG, Taylor-Cousar JL. Outcomes of pregnancy in women with cystic fibrosis (CF) taking CFTR modulators - an international survey. J Cyst Fibros. 2020;19(4):521-526.

  8. Taylor-Cousar JL, Jain R. Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation. J Cyst Fibros. 2021;20(3):402-406.

  9. Kolaczkowski TJ, Bevan A, Legg J, Self J, Allenby M. Elevated liver function tests in infants exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breastfeeding - Case reports. J Cyst Fibros. 2024

  10. Fortner CN, Seguin JM, Kay DM. Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy. J Cyst Fibros. 2021;20(5):835-836.

  11. D'Atri V, Corrado F, Versace F, Saldanha SA, Mercier T, Guidi M et al. A Liquid Chromatography-Tandem Mass Spectrometry Method for the Quantification of Cystic Fibrosis Drugs (Caftors) in Plasma and Its Application for Therapeutic Monitoring. Molecules. 2025;30(9):.

  12. Destoop M, Brantner C, Wilms EB, Tytgat S, Peels B, van der Graaf R et al. CFTR modulator therapy via carrier mother to treat meconium ileus in a F508del homozygous fetus: Insights from an unsuccessful case. J Cyst Fibros. 2025;24(3):476-478.

  13. Sinkey RG, Garcia B, Fowler CM, Krick S, Ryan KJ, Acosta EP et al. Pharmacokinetic assessment of elexacaftor/tezacaftor/ivacaftor and their metabolites in maternal blood, cord blood, the neonate, and breastmilk of a cystic fibrosis carrier mother/affected fetus dyad. J Cyst Fibros. 2026;25(1):28-31.

  14. Gariti A, Johnson R, Moonnumakal S, Placencia F, Sawyer K, Mann DG. Harm reduction in paediatric off-label therapy: ethical analysis of early CFTR modulator use in an infant with cystic fibrosis. J Med Ethics. 2026.

  1. Trimble A, McKinzie C, Terrell M, Stringer E, Esther CR. Measured fetal and neonatal exposure to Lumacaftor and Ivacaftor during pregnancy and while breastfeeding. J Cyst Fibros. 2018;17(6):779-782.
  2. Collins B, Fortner C, Cotey A, Jr CRE, Trimble A. Drug exposure to infants born to mothers taking Elexacaftor, Tezacaftor, and Ivacaftor. J Cyst Fibros. 2021;21(21):S1569-1993(21)02161-5.
  3. Ripani P, Mucci M, Pantano S, Di Sabatino M, Collini F, Ferri G et al. Maternal, newborn and breast milk concentrations of elexacaftor/tezacaftor/ivacaftor in a F508del heterozygous woman with cystic fibrosis following successful pregnancy. Front Med (Lausanne). 2023;10:1274303.
  4. Jain R, Wolf A, Molad M, Taylor-Cousar J, Esther CR, Shteinberg M. Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feeding. J Cyst Fibros. 2022;21(6):1074-1076.
  5. Goodwin J, Quon BS, Wilcox PG. Experience to date with CFTR modulators during pregnancy and breastfeeding in the British Columbia Cystic Fibrosis clinic. Respir Med Case Rep. 2022;40:101778.
  6. Bergeron S, Audousset C, Bourdon G, Garabedian C, Gautier S. Elexacaftor/tezacaftor/ivacaftor induced liver enzymes abnormalities in breastfed infants: A series of 3 cases. Therapie. 2024
  7. Nash EF, Middleton PG, Taylor-Cousar JL. Outcomes of pregnancy in women with cystic fibrosis (CF) taking CFTR modulators - an international survey. J Cyst Fibros. 2020;19(4):521-526.
  8. Taylor-Cousar JL, Jain R. Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation. J Cyst Fibros. 2021;20(3):402-406.
  9. Kolaczkowski TJ, Bevan A, Legg J, Self J, Allenby M. Elevated liver function tests in infants exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breastfeeding - Case reports. J Cyst Fibros. 2024
  10. Fortner CN, Seguin JM, Kay DM. Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy. J Cyst Fibros. 2021;20(5):835-836.
  11. D'Atri V, Corrado F, Versace F, Saldanha SA, Mercier T, Guidi M et al. A Liquid Chromatography-Tandem Mass Spectrometry Method for the Quantification of Cystic Fibrosis Drugs (Caftors) in Plasma and Its Application for Therapeutic Monitoring. Molecules. 2025;30(9):.
  12. Destoop M, Brantner C, Wilms EB, Tytgat S, Peels B, van der Graaf R et al. CFTR modulator therapy via carrier mother to treat meconium ileus in a F508del homozygous fetus: Insights from an unsuccessful case. J Cyst Fibros. 2025;24(3):476-478.
  13. Sinkey RG, Garcia B, Fowler CM, Krick S, Ryan KJ, Acosta EP et al. Pharmacokinetic assessment of elexacaftor/tezacaftor/ivacaftor and their metabolites in maternal blood, cord blood, the neonate, and breastmilk of a cystic fibrosis carrier mother/affected fetus dyad. J Cyst Fibros. 2026;25(1):28-31.
  14. Gariti A, Johnson R, Moonnumakal S, Placencia F, Sawyer K, Mann DG. Harm reduction in paediatric off-label therapy: ethical analysis of early CFTR modulator use in an infant with cystic fibrosis. J Med Ethics. 2026.

Innehållet senast uppdaterat 4/29/2026

2 2
2 2

Tezakaftor

Tezakaftor

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Collins B, Fortner C, Cotey A, Jr CRE, Trimble A. Drug exposure to infants born to mothers taking Elexacaftor, Tezacaftor, and Ivacaftor. J Cyst Fibros. 2021;21(21):S1569-1993(21)02161-5.

  2. Jain R, Wolf A, Molad M, Taylor-Cousar J, Esther CR, Shteinberg M. Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feeding. J Cyst Fibros. 2022;21(6):1074-1076.

  3. Ripani P, Mucci M, Pantano S, Di Sabatino M, Collini F, Ferri G et al. Maternal, newborn and breast milk concentrations of elexacaftor/tezacaftor/ivacaftor in a F508del heterozygous woman with cystic fibrosis following successful pregnancy. Front Med (Lausanne). 2023;10:1274303.

  4. Bergeron S, Audousset C, Bourdon G, Garabedian C, Gautier S. Elexacaftor/tezacaftor/ivacaftor induced liver enzymes abnormalities in breastfed infants: A series of 3 cases. Therapie. 2024

  5. Nash EF, Middleton PG, Taylor-Cousar JL. Outcomes of pregnancy in women with cystic fibrosis (CF) taking CFTR modulators - an international survey. J Cyst Fibros. 2020;19(4):521-526.

  6. Taylor-Cousar JL, Jain R. Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation. J Cyst Fibros. 2021;20(3):402-406.

  7. Goodwin J, Quon BS, Wilcox PG. Experience to date with CFTR modulators during pregnancy and breastfeeding in the British Columbia Cystic Fibrosis clinic. Respir Med Case Rep. 2022;40:101778.

  8. Kolaczkowski TJ, Bevan A, Legg J, Self J, Allenby M. Elevated liver function tests in infants exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breastfeeding - Case reports. J Cyst Fibros. 2024

  9. Fortner CN, Seguin JM, Kay DM. Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy. J Cyst Fibros. 2021;20(5):835-836.

  10. D'Atri V, Corrado F, Versace F, Saldanha SA, Mercier T, Guidi M et al. A Liquid Chromatography-Tandem Mass Spectrometry Method for the Quantification of Cystic Fibrosis Drugs (Caftors) in Plasma and Its Application for Therapeutic Monitoring. Molecules. 2025;30(9):.

  11. Destoop M, Brantner C, Wilms EB, Tytgat S, Peels B, van der Graaf R et al. CFTR modulator therapy via carrier mother to treat meconium ileus in a F508del homozygous fetus: Insights from an unsuccessful case. J Cyst Fibros. 2025;24(3):476-478.

  12. Sinkey RG, Garcia B, Fowler CM, Krick S, Ryan KJ, Acosta EP et al. Pharmacokinetic assessment of elexacaftor/tezacaftor/ivacaftor and their metabolites in maternal blood, cord blood, the neonate, and breastmilk of a cystic fibrosis carrier mother/affected fetus dyad. J Cyst Fibros. 2026;25(1):28-31.

  13. Gariti A, Johnson R, Moonnumakal S, Placencia F, Sawyer K, Mann DG. Harm reduction in paediatric off-label therapy: ethical analysis of early CFTR modulator use in an infant with cystic fibrosis. J Med Ethics. 2026.

  1. Collins B, Fortner C, Cotey A, Jr CRE, Trimble A. Drug exposure to infants born to mothers taking Elexacaftor, Tezacaftor, and Ivacaftor. J Cyst Fibros. 2021;21(21):S1569-1993(21)02161-5.
  2. Jain R, Wolf A, Molad M, Taylor-Cousar J, Esther CR, Shteinberg M. Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feeding. J Cyst Fibros. 2022;21(6):1074-1076.
  3. Ripani P, Mucci M, Pantano S, Di Sabatino M, Collini F, Ferri G et al. Maternal, newborn and breast milk concentrations of elexacaftor/tezacaftor/ivacaftor in a F508del heterozygous woman with cystic fibrosis following successful pregnancy. Front Med (Lausanne). 2023;10:1274303.
  4. Bergeron S, Audousset C, Bourdon G, Garabedian C, Gautier S. Elexacaftor/tezacaftor/ivacaftor induced liver enzymes abnormalities in breastfed infants: A series of 3 cases. Therapie. 2024
  5. Nash EF, Middleton PG, Taylor-Cousar JL. Outcomes of pregnancy in women with cystic fibrosis (CF) taking CFTR modulators - an international survey. J Cyst Fibros. 2020;19(4):521-526.
  6. Taylor-Cousar JL, Jain R. Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation. J Cyst Fibros. 2021;20(3):402-406.
  7. Goodwin J, Quon BS, Wilcox PG. Experience to date with CFTR modulators during pregnancy and breastfeeding in the British Columbia Cystic Fibrosis clinic. Respir Med Case Rep. 2022;40:101778.
  8. Kolaczkowski TJ, Bevan A, Legg J, Self J, Allenby M. Elevated liver function tests in infants exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breastfeeding - Case reports. J Cyst Fibros. 2024
  9. Fortner CN, Seguin JM, Kay DM. Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy. J Cyst Fibros. 2021;20(5):835-836.
  10. D'Atri V, Corrado F, Versace F, Saldanha SA, Mercier T, Guidi M et al. A Liquid Chromatography-Tandem Mass Spectrometry Method for the Quantification of Cystic Fibrosis Drugs (Caftors) in Plasma and Its Application for Therapeutic Monitoring. Molecules. 2025;30(9):.
  11. Destoop M, Brantner C, Wilms EB, Tytgat S, Peels B, van der Graaf R et al. CFTR modulator therapy via carrier mother to treat meconium ileus in a F508del homozygous fetus: Insights from an unsuccessful case. J Cyst Fibros. 2025;24(3):476-478.
  12. Sinkey RG, Garcia B, Fowler CM, Krick S, Ryan KJ, Acosta EP et al. Pharmacokinetic assessment of elexacaftor/tezacaftor/ivacaftor and their metabolites in maternal blood, cord blood, the neonate, and breastmilk of a cystic fibrosis carrier mother/affected fetus dyad. J Cyst Fibros. 2026;25(1):28-31.
  13. Gariti A, Johnson R, Moonnumakal S, Placencia F, Sawyer K, Mann DG. Harm reduction in paediatric off-label therapy: ethical analysis of early CFTR modulator use in an infant with cystic fibrosis. J Med Ethics. 2026.

Innehållet senast uppdaterat 4/29/2026